Pharma Plus: Merck’s Global Health Innovation Fund
Realizing that future winners in the health care world will be those companies with broad-based and comprehensive health care offerings, Merck & Co. Inc. tasked a group of executives with identifying and pursuing investment opportunities in what it calls health care adjacencies.
You may also be interested in...
Armed with financing from a syndicate including Merck’s Global Health Innovation Fund, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. The company believes its noninvasive vagus nerve stimulator that is self-administered by the patient could potentially upturn treatment paradigms.
Armed with a $40 million Series A financing, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. With drug firms upping their interest in so-called “electroceuticals,” it could signal a shift away from certain pharmaceutical treatments.
Three years into the ACA, the biopharma industry takes stock of its near-term wins and losses as the law’s critical expanded insurance coverage takes effect beginning in 2014. Pharma still isn’t sure whether the increase in covered lives from the exchanges will boost prescription sales enough to offset the rebates, taxes, and fees it agreed to pay out, or what kind of patients constitute this new market.